Rash relief? antifungal drug shows promise for cancer treatment side effect

NCT ID NCT03471364

Completed Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether ketoconazole, an antifungal drug, can reduce the skin rash caused by EGFR inhibitor cancer therapy. 58 participants with ongoing rash were given either ketoconazole or a placebo. The main goal was to see if the drug improved rash symptoms and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM

Contacts and locations

Locations

Carle Cancer Center

Urbana, Illinois, 61801, United States
Carle on Vermilion

Danville, Illinois, 61832, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Park Nicollet Frauenshuh Cancer Center

Saint Louis Park, Minnesota, 55426, United States
Regions Hospital

Saint Paul, Minnesota, 55101, United States
University of Rochester

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.